NYXH
Nyxoah S.A.
There isn't enough reported data to score NYXH yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
NYXH Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Weak | |
| Unavailable |
NYXH's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
NYXH PE Valuation
NYXH has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
NYXH Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Moderate |
Analysts expect NYXH's losses to shrink, with revenue growing.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
NYXH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$2.41 | -$0.07 |
| Q1 2026 | -$2.38 | -$0.17 |
| Q4 2025 | -$2.63 | -$0.62 |
| Q3 2025 | -$2.49 | -$0.57 |
| Q2 2025 | -$2.34 | -$0.67 |
| Q1 2025 | -$2.21 | -$0.52 |
| Q4 2024 | -$2.01 | -$0.28 |
| Q3 2024 | -$1.92 | -$0.04 |
NYXH lost $2.41 per share over the past year, about the same as its loss the year before.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over NYXH on earnings quality, reporting a profit while its opponent remains loss making.
NYXH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $8.5M | +473% |
| Q1 2026 | $8.2M | +592% |
| Q4 2025 | $6.3M | +347% |
| Q3 2025 | $2.2M | +56% |
| Q2 2025 | $1.5M | +74% |
| Q1 2025 | $1.2M | -13% |
| Q4 2024 | $1.4M | -31% |
| Q3 2024 | $1.4M | +30% |
NYXH's revenue has grown year over year for five quarters in a row: $9M last quarter, up 473% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -268% | +1213 points |
| Q1 2026 | -322% | +1617 points |
| Q4 2025 | -324% | +1126 points |
| Q3 2025 | -1227% | -44 points |
| Q2 2025 | -1481% | +245 points |
| Q1 2025 | -1940% | -940 points |
| Q4 2024 | -1450% | -856 points |
| Q3 2024 | -1183% | -58 points |
NYXH's operating margin was −268% last quarter, up 1213 points from the same quarter a year ago, near the top of its range since 2020.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR's revenue has grown year over year every quarter since early 2021: $5.1B last quarter, up 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over NYXH on profitability, with a higher operating margin.
NYXH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$19.8M | -$639.9K |
| Q1 2026 | -$24.8M | -$4M |
| Q4 2025 | -$14.6M | +$682K |
| Q3 2025 | -$22.8M | -$7M |
| Q2 2025 | -$19.2M | -$5.2M |
| Q1 2025 | -$20.8M | -$4.5M |
| Q4 2024 | -$15.3M | -$369.9K |
| Q3 2024 | -$15.8M | -$40K |
NYXH has burned cash in almost every quarter: −$82M over the past year, against −$71M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over NYXH on cash generation, producing positive trailing cash flow while its opponent burns cash.
NYXH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +32% | +13.8M shares |
| 1 year | +52% | +19.6M shares |
| 3 years | +99% | +28.4M shares |
| 5 years | +158% | +34.9M shares |
| Available history | +376% | +45M shares |
NYXH has 57M diluted shares, up 52% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
NYXH hasn't bought back shares in the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over NYXH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
NYXH Net Leverage
NYXH's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
NYXH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 26.6 | Oversold |
| Stochastic | 6.9 | Oversold |
NYXH's weekly RSI is 27 (oversold) and its Stochastic is 7 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
NYXH PE vs Healthcare Sector
NYXH has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
NYXH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.09 | 17% below |
| 20 week MA | $1.37 | 34% below |
| 50 week MA | $2.70 | 67% below |
| 100 week MA | $5.04 | 82% below |
| 200 week MA | $6.61 | 86% below |
NYXH is in a downtrend: it's below all five of its weekly moving averages, and 86% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over NYXH on trend strength, trading above more of its moving averages.
NYXH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $24.0 | $21.0 | -12% |
| 2022 | $21.0 | $5.20 | -75% |
| 2023 | $5.20 | $4.64 | -11% |
| 2024 | $4.64 | $8.00 | +72% |
| 2025 | $8.00 | $4.47 | -44% |
| 2026 YTD | $4.47 | $0.90 | -80% |
NYXH has finished lower in four of the last five years. It's down 80% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over NYXH on returns for 2026, with the stronger performance.